Diabetes Reversal Without Drugs Enters Corporate Health Benefits

ALPHARETTA, Ga. – April 23, 2026 – In a significant move that could reshape how employers address chronic disease, digital health firm Heald announced it is partnering with the benefits platform Thatch to offer the first dedicated diabetes reversal program on its marketplace. The collaboration gives millions of employees tax-free access to Heald’s program, which focuses on reversing type 2 diabetes through lifestyle changes rather than lifelong medication, providing a stark alternative to the pharmaceutical-heavy approach that has long dominated care.

This partnership arrives at a critical juncture in healthcare. Employers are grappling with soaring insurance costs, while employees are demanding more personalized and flexible benefits. Simultaneously, the meteoric rise of GLP-1 drugs like Ozempic and Wegovy has highlighted a massive demand for effective metabolic health solutions, but has also raised questions about cost, long-term dependency, and side effects. By integrating a non-pharmacological, results-guaranteed program directly into a modern benefits ecosystem, Heald and Thatch are betting on a new paradigm for corporate wellness: root-cause resolution funded by the employer.

The New Model for Corporate Health

The foundation of this partnership is Thatch's innovative benefits model, built on Individual Coverage Health Reimbursement Arrangements (ICHRAs). An ICHRA is a tax-advantaged framework, established in 2020, that allows companies to provide employees with a monthly allowance. Employees then use these funds to purchase their own individual health insurance plans and cover other qualified medical expenses. This approach offers predictable costs for employers, who set a fixed budget, and greater choice for employees, who can select plans that best fit their needs.

Thatch, a San Francisco-based startup, has become a major force in this space, having raised over $84 million in funding and onboarding more than a thousand companies. Its platform simplifies the ICHRA process and includes the Thatch Marketplace, a curated ecosystem of health and wellness services. The inclusion of Heald marks the marketplace’s first foray into specialized, root-cause-focused care for a major chronic condition.

"We are thrilled to welcome Heald to the Thatch Marketplace as our inaugural diabetes reversal partner," said Chris Ellis, CEO and Co-founder at Thatch. "Our goal is to put employees in control of their health by giving them the ability to select the benefits and care they actually value. Heald’s personalized, evidence-based model is exactly the kind of high-impact service we want to make available."

This model is gaining significant traction. From 2024 to 2025 alone, ICHRA adoption grew by 34% among large employers. The trend reflects a broader shift away from one-size-fits-all group plans toward benefits that cater to a diverse workforce with varied health needs.

The Promise of Reversal, Beyond the Prescription Pad

Heald’s program distinguishes itself by aiming for diabetes reversal—a state of remission recognized by leading medical bodies like the American Diabetes Association (ADA). The ADA defines remission as maintaining an A1C level below 6.5% for at least three months without the use of glucose-lowering medications. This is precisely the goal of Heald’s doctor-led, psychology-based approach.

The company’s money-back guaranteed program is built on a holistic, 5-point healing plan that addresses diet, activity, sleep, stress, and medication management. It combines a mobile app, 24/7 AI coaching, and a human care team to provide both clinical and emotional support. Heald reports significant outcomes from this model, including an average A1C reduction of 3% and an average weight loss of 11 pounds.

Critically, these results are achieved without prescribing GLP-1s. Instead, the program focuses on sustainable behavioral science to empower individuals to improve their metabolic health naturally.

"For too long, the healthcare system has focused on managing symptoms rather than reversing the underlying causes of chronic disease," stated Sandeep Misra, Co-Founder & Chief Growth Officer at Heald. "This partnership allows us to bring our results-driven... diabetes reversal program to a wider audience, empowering them to take control of their health with the support of their employer's benefits."

This focus on sustainable change has reportedly enabled 98% of Heald users to reduce their medication dependency. This positions the program not only as a primary intervention but also as a potential solution for those seeking a way to maintain health without long-term reliance on pharmaceuticals.

An 'Off-Ramp' from the GLP-1 Boom?

The timing of this partnership is particularly notable given the widespread use of GLP-1 medications. While effective for weight loss and blood sugar control, these drugs are expensive and designed for long-term, if not lifelong, use. Many patients and payers are actively seeking sustainable alternatives or a strategy to discontinue the drugs without regaining weight or losing glycemic control.

Heald is explicitly positioning its program as a safe and effective “off-ramp” from GLP-1s, to be used in consultation with a patient's primary physician. By teaching the fundamental lifestyle and behavioral skills necessary for metabolic health, the program aims to provide a pathway to maintaining results after stopping medication. This angle directly addresses a growing concern in the healthcare market: what happens next for the millions of people on GLP-1s?

By making this service an accessible, pre-approved option within the Thatch Marketplace, employees gain a clear, financially viable path to explore a non-pharmacological route to managing their condition, a choice that might otherwise be complex and costly to pursue.

A Strategic Play in a Crowded Market

The digital health landscape for diabetes care is competitive, with established players like Virta Health, which focuses on a ketogenic diet, and Omada Health and Livongo, which also use coaching and technology for chronic disease management. However, the Heald-Thatch partnership represents a unique strategic alignment of a care provider and a benefits delivery platform.

For Heald, the collaboration provides direct access to a large, motivated customer base and a streamlined payment channel through employer-funded allowances. It differentiates Heald by embedding its service directly into the corporate benefits selection process. For Thatch, adding a specialized, high-demand service like a GLP-1 alternative strengthens its value proposition to employers seeking to offer cutting-edge, cost-effective health solutions.

By joining forces, the two companies are creating a powerful, integrated offering that addresses multiple pain points in the healthcare system: accessibility for patients, cost control for employers, and a focus on sustainable, long-term health outcomes over perpetual symptom management. This partnership may serve as a blueprint for how specialized digital health solutions are delivered and financed in the future, moving them from the fringes of wellness to the core of employee health benefits.